Aurinia Pharmaceuticals Inc. (AUPH) stock
AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3062% below fair value
$15.73−0.48 (-2.96%)
Close on Nov 13, 2026Market cap $2.11BP/E 6.9Yield –
Aurinia Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Aurinia Pharmaceuticals's enterprise value was $1.97B on Nov 11, 2026, against $2.05B a year earlier. Over the last 5 years it ranged from $528.57M to $2.91B, with a median of $1.23B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.97B | -2.7% |
| 2025 | Dec 31, 2025 | $2.03B | +62.6% |
| 2024 | Dec 31, 2024 | $1.25B | +0.2% |
| 2023 | Dec 29, 2023 | $1.25B | +135.6% |
| 2022 | Dec 30, 2022 | $528.57M | -81.8% |
| 2021 | Dec 31, 2021 | $2.91B | +134.3% |
| 2020 | Dec 31, 2020 | $1.24B | -23.2% |
| 2019 | Dec 31, 2019 | $1.61B | +349.7% |
| 2018 | Dec 31, 2018 | $358.95M | +198.6% |
| 2017 | Dec 29, 2017 | $120.19M | – |
See a number that looks wrong?